Radiological Features of Metastatic Gastrointestinal Stromal Tumors

Patnaik, Sujata; Jyotsnarani, Yarlagadda; Rammurti, S.

doi:10.4103/2156-7514.99177

Cited by 26 publications

(47 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Yang et al described transformation of metastases into pseudocysts with clearly discernible contours of lesions, which had features of simple cysts also in ultrasonography, additionally increasing the chance of misinterpretation [ 15 ]. Similar transformations of solid tumors into pseudocystic lesions in CT scans were shown by Patnaik et al [ 16 ].…”

Section: Discussionsupporting

confidence: 80%

Evaluation of Alterations in Tumor Tissue of Gastrointestinal Stromal Tumor (GIST) in Computed Tomography Following Treatment with Imatinib

2018

View full text Add to dashboard Cite

SummaryBackgroundThe aim of this study was to evaluate the alterations in the neoplastic tissue of GIST following Imatinib treatment.Material/MethodsCT studies of 14 patients with inoperable primary tumors and 56 patients with metastatic and recurrent disease after chemotherapy were analyzed retrospectively. The following alterations in features of primary and secondary tumors were analyzed: dimension, degree and type of contrast enhancement, outlines of lesions, presence of intratumoral bleeding, presence of calcifications.ResultsIn the analyzed group of primary, metastatic and recurrent tumors after treatment with Imatinib in most cases a decrease in size and contrast enhancement were observed; the outlines of lesions became well circumscribed. Following the treatment, the number of tumors enhancing inhomogeneously decreased. In primary tumors the percentage of calcifications increased, whereas in metastatic tumors calcifications were observed only after treatment. There was no bleeding found within primary tumors after treatment. In metastatic disease, increased percentage of tumors with transient intratumoral bleeding was observed. There were also some unconventional CT images following treatment, such as: cystic transformation of lesions, enlargement of lesions, appearing of new lesions suggesting progression of the disease, stationary dimensions of lesions during local progression of the disease, simultaneous decrease and increase in size of metastatic lesions or appearance of new ones.ConclusionsRight from the start of Imatinib therapy in inoperable and disseminated GIST patients, specific CT images, not seen during conventional cytotoxic chemotherapy, were observed.

show abstract

Section: Discussionsupporting

confidence: 80%

Evaluation of Alterations in Tumor Tissue of Gastrointestinal Stromal Tumor (GIST) in Computed Tomography Following Treatment with Imatinib

2018

View full text Add to dashboard Cite

show abstract

“…Larger tumours appear as lobulated, hypervascular masses that may displace adjacent structures. These often enhance heterogeneously because of cystic degeneration and central liquefactive necrosis 14. Almost half of the patients in our study had reported necrosis on imaging.…”

Section: Discussionmentioning

confidence: 65%

Gastrointestinal stromal tumours (GISTs): an insight into clinical practice with review of literature

McDonnell

Punnoose

Viswanath

et al. 2016

Frontline Gastroenterol

View full text Add to dashboard Cite

show abstract

“…As reported from other studies [15,16] liver was the most common site of metastasis in our patients. However, pulmonary metastases, which have been described as 'rare' in GISTs [17], and a sign of advanced disease [4], was the second most common site of metastases in our study. This may indicate that at presentation, a higher proportion of GIST patients from this region are already having advanced disease.…”

mentioning

confidence: 52%

Gastrointestinal stromal tumors in southern Iraq: clinico-pathologic patterns and risk stratification

2018

ajbm

View full text Add to dashboard Cite

There was no local or nationwide data on the patterns of Gastrointestinal Stromal Tumors (GISTs) in Iraq. This study was undertaken to determine the clinical and pathologic characteristics and risk stratification of GISTs in Iraqi patients over a nine years' period. This is a retrospective descriptive study. Medical notes and histopathological reports of patients with confirmed diagnosis of GIST between January 2007 and August 2015 were reviewed for age, gender, tumor location, CD117 status, tumor stage, and National Institutes of Health (NIH) risk classification. Fortyseven patients were included in the study. Mean age at time of diagnosis was 57 years (range 29 to 85 years), and male to female ratio was 1:1. Most common sites of involvement of GISTs were stomach (21/47), and jejunum/ ileum (16/47). Immunohistochemistry for CD117 was positive in 33 cases. Out of the 47 cases, 4 were locally advanced and 15 were metastasized. The most common site for metastasis was liver (53%) followed by pulmonary (40%) and retroperitoneum (7%). Risk stratification was done for only 41 cases; 61% were stratified as high risks group, 12% belonged to intermediate risk category, while the rest 27% were stratified as very low and low risk groups. While the epidemiological patterns of GIST from Iraq resembles those from elsewhere, the disease was more advanced in Iraqi patients when compared to Western countries. At the time of diagnosis, majority of our cases were stratified under high-risk category.

show abstract

Radiological Features of Metastatic Gastrointestinal Stromal Tumors

Cited by 26 publications

References 14 publications

Evaluation of Alterations in Tumor Tissue of Gastrointestinal Stromal Tumor (GIST) in Computed Tomography Following Treatment with Imatinib

Evaluation of Alterations in Tumor Tissue of Gastrointestinal Stromal Tumor (GIST) in Computed Tomography Following Treatment with Imatinib

Gastrointestinal stromal tumours (GISTs): an insight into clinical practice with review of literature

Gastrointestinal stromal tumors in southern Iraq: clinico-pathologic patterns and risk stratification

Contact Info

Product

Resources

About